News|Articles|May 28, 2025
Do New Antiobesity Meds Still Require Lifestyle Management?
Listen
0:00 / 0:00
Key Takeaways
- Pharmacotherapy targets appetite signaling, yet lifestyle modification addresses environmental and behavioral drivers that medications cannot fully correct, particularly for cardiometabolic comorbidity control.
- Intensive behavioral therapy provides structured goal setting, self‑monitoring, and problem solving that improves adherence to GLP‑1/GIP agents and sustains weight loss trajectories.
Are lifestyle interventions still necessary when medications like semaglutide and tirzepatide are so effective?
Learn How To Introduce a Turnkey Evidence Based Nutrition Counseling Program to Your Practice.
Discover evidence-based guidance on how and why lifestyle counseling remains a cornerstone of obesity care—even in the era of highly effective, hormone-based pharmacotherapy.
Inside you'll learn:
- Why lifestyle management remains foundational—even with GLP-1 and GIP-based medications
- The clinical value of intensive behavioral therapy (IBT) alongside pharmacologic treatment
- Key findings from STEP, SURMOUNT, and Look AHEAD trials
Adding a lifestyle management nutrition counseling program to your practice has both clinical and economic benefits.
Sponsored by:
Related Content
Trending on Medical Economics
1
Physician practice bankruptcies on pace for their highest level since 2019
2
eClinicalWorks on the Future of Rural Healthcare: Five Strategies to Improve Access, Financial Sustainability, and Outcomes
3
Why value-based care still hasn't replaced fee-for-service — and maybe never will
4
How can primary care Make America Healthy Again? CMS wants to know
5